.png)
Summary
Data Protection: Addressing Noise, Speech, and Voice Concerns
Here's our newest conversation with Brij Mohan Lal Srivastava, CEO and Co-founder of Nijta, a company at the forefront of AI in speech anonymization. The realm of voice is an emerging and fascinating area within the life sciences, and with every new domain, issues of privacy come to the forefront.
In this discussion, we converse with Brij Mohan Lal Srivastava, who is the co-founder and CEO of Nijta, a company that focuses on developing AI-powered solutions for data anonymization and pseudonymization. These solutions are becoming increasingly important in clinical research, particularly with the emergence of voice as an important biomarker for identifying diseases such as depression. We delve into the fundamentals of noise, speech, and voice, and also explore how Nijta's technologies can be applied in the life sciences sector.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Data Protection Strategies for Phase III Clinical Trials
Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2
Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.
Interview Paul Chilo Director of Governance, Risk & Compliance at SOPHiA GENETICS - SOPHiA UNITY
